Cardiff Oncology

CRDF · NASDAQ

$0.9315+$0.0458 (+5.17%)TodayMarket closed · Oct 20, 7:33 PM ET

Prev close $0.8857

Latest news

Press releaseSep 14, 8:30 AM ETGlobe Newswire
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
NewsAug 11, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseAug 11, 4:10 PM ETGlobe Newswire
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
NewsJul 15, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsJul 15, 12:03 PM ETAvi Kapoor
Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June
NewsJul 15, 9:43 AM ETAvi Kapoor
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
Press releaseJul 15, 8:00 AM ETGlobe Newswire
Cardiff Oncology Announces $10 Million Registered Direct Offering
Press releaseJun 2, 9:06 AM ETGlobe Newswire
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Press releaseMay 21, 5:00 PM ETGlobe Newswire
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
NewsMay 20, 2:11 PM ETVandana Singh
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Press releaseMay 14, 4:10 PM ETGlobe Newswire
Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update
Press releaseApr 21, 10:00 AM ETGlobe Newswire
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Press releaseApr 17, 4:01 PM ETGlobe Newswire
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Press releaseApr 9, 4:01 PM ETGlobe Newswire
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
NewsJan 27, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseDec 12, 10:31 AM ETGlobe Newswire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
NewsAug 6, 9:02 AM ET
A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts
NewsJul 30, 3:27 PM ETVandana Singh
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?
NewsJul 30, 1:07 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsJul 30, 8:08 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsJul 30, 8:05 AM ETAvi Kapoor
Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
NewsJul 29, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseJul 29, 4:05 PM ETGlobe Newswire
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
Press releaseJul 8, 8:50 AM ETGlobe Newswire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
Press releaseJun 17, 4:05 PM ETGlobe Newswire
Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC
Press releaseMar 8, 7:33 AM ETPRNewswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Press releaseFeb 20, 4:05 PM ETGlobe Newswire
Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update
Press releaseDec 26, 9:00 AM ETGlobe Newswire
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
Press releaseDec 20, 12:52 PM ETPRNewswire
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
Press releaseDec 18, 11:12 AM ETPRNewswire
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments
NewsDec 10, 10:34 AM ETPiero Cingari
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'
Press releaseAug 8, 4:05 PM ETGlobe Newswire
Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update
Press releaseAug 1, 4:05 PM ETGlobe Newswire
Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement

12 Health Care Stocks Moving In Tuesday's After-Market Session

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

12 Health Care Stocks Moving In Wednesday's Intraday Session

Crude Oil Moves Lower; US Producer Prices Fall 0.3% In June

Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views

Cardiff Oncology Announces $10 Million Registered Direct Offering

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC

Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense

Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth

12 Health Care Stocks Moving In Tuesday's Intraday Session

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Avis Budget Group Posts Downbeat Earnings, Joins SoFi Technologies, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift'

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update